Search

Your search keyword '"Stefic, Karl"' showing total 176 results
Start Over Author "Stefic, Karl"
176 results on '"Stefic, Karl"'

2. Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs

Author

Wang, Chuangqi, Schlub, Timothy E, Yu, Wen Han, Tan, C Sabrina, Stefic, Karl, Gianella, Sara, Smith, Davey M, Lauffenburger, Douglas A, Chaillon, Antoine, and Julg, Boris

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Clinical Research, HIV/AIDS, Infectious Diseases, Prevention, Infection, Good Health and Well Being, Antibodies, Neutralizing, Bayes Theorem, Broadly Neutralizing Antibodies, Epitopes, HIV Antibodies, HIV Infections, HIV-1, Humans, Neutralization Tests, Polysaccharides, env Gene Products, Human Immunodeficiency Virus, HIV, neutralization susceptibilities, bNAbs, tissues, prediction modeling, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundHuman immunodeficiency virus type 1 (HIV-1) sequence diversity and the presence of archived epitope muta-tions in antibody binding sites are a major obstacle for the clinical application of broadly neutralizing antibodies (bNAbs) against HIV-1. Specifically, it is unclear to what degree the viral reservoir is compartmentalized and if virus susceptibility to antibody neutralization differs across tissues.MethodsThe Last Gift cohort enrolled 7 people with HIV diagnosed with a terminal illness and collected antemortem blood and postmortem tissues across 33 anatomical compartments for near full-length env HIV genome sequencing. Using these data, we applied a Bayesian machine-learning model (Markov chain Monte Carlo-support vector machine) that uses HIV-1 envelope sequences and approximated glycan-occupancy information to quantitatively predict the half-maximal inhib-itory concentrations (IC50) of bNAbs, allowing us to map neutralization resistance pattern across tissue reservoirs.ResultsPredicted mean susceptibilities across tissues within participants were relatively homogenous, and the susceptibility pattern observed in blood often matched what was predicted for tissues. However, selected tissues, such as the brain, showed ev-idence of compartmentalized viral populations with distinct neutralization susceptibilities in some participants. Additionally, we found substantial heterogeneity in the range of neutralization susceptibilities across tissues within and between indi-viduals, and between bNAbs within individuals (standard deviation of log2(IC50) >3.4).ConclusionsBlood-based screening methods to determine viral susceptibility to bNAbs might underestimate the presence of resistant viral variants in tissues. The extent to which these resistant viruses are clinically relevant, that is, lead to bNAb therapeutic failure, needs to be further explored.

Published
2022

3. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

Author

Moreno, Santiago, Burns, Fiona, Campo, Rafael Eduardo, Garges, Harmony, Mussini, Cristina, Pantazis, Nikos, Kamel, Moustafa, Porter, Kholoud, Sabin, Caroline, Tariq, Shema, Touloumi, Giota, Vannappagari, Vani, Anne, Alain Volny, Young, Lital, Gill, John, Carlander, Christina, Grabar, Sophie, Jarrín, Inma, Meyer, Laurence, van der Valk, Marc, Wittkop, Linda, Aisam, Agnes, Barger, Diana, Davidovich, Udi, Dos Santos, Marie, Eriksson, Lars, Fitzgerald, Eli, Karakosta, Argyro, Krentz, Hartmut, Nicholls, Emily Jay, Policek, Nicoletta, Ruiz-Burga, Elisa, Sandford, Chris, Spire, Bruno, Suárez-García, Inés, Abgrall, Sophie, Andriantsoanirina, Valerie, Avettand-Fenoel, Veronique, Bourgeois, Christine, Chaix, Marie-Laure, Cheret, Antoine, Fischer, Hugues, Goujard, Cecile, Lascoux-Combe, Caroline, Le Palec, Annie, Petrov-Sanchez, Ventzlislava, Saez-Cirion, Asier, Seng, Remonie, Stefic, Karl, Tine, Josephine, Piet, E, Gagneux-Brunon, A, Jacomet, C, Piroth, L, Benezit, F, Goussef, M, Tattevin, P, Bani Sadr, B, Lamaury, I, Bazus, H, Robineau, O, Calin, R, Katlama, J, Denis, B, Ghosn, J, Joly, V, Khuong, M A, Caby, F C, Rouveix Nordon, E, de Truchis, P, Abgrall, S, Chéret, A, Duvivier, C, Becker, A, Miailhes, P, Abel, S, Unal, G, Makinson, A, Martin-Blondel, G, Morisot, A, Bregigeon, S, Enel, P, Allavena, C, Rabier, V, Vallet, L, Marchand, L, Saïdi, T, Costagliola, D, Grabar, S, Andriantsoanirina, V, Fischer, H, Marchand T Saïdi, L, Tattevin, Pierre, de Truchis, Pierre, Fischer, Hughes, Dalmau, David, Navarro, M Luisa, González, M Isabel, Garcia, Federico, Poveda, Eva, Iribarren, Jose Antonio, Gutiérrez, Félix, Rubio, Rafael, Vidal, Francesc, Berenguer, Juan, Muñoz-Fernández, M Ángeles, Adamis, G, Chini, M, Chrysos, G, Marangos, M, Katsarou, O, Kofteridis, D, Metallidis, S, Panagopoulos, P, Papadopoulos, A, Paparizos, V, Psychogiou, M, Sambatakou, H, Sipsas, N V, Touloumi, G, Fox, Julie, Terry, Louise, Waters, Anele, Uriel, Alison, Ustianowski, Andrew, Hackney, Pamela, Fahd, Niaz, Fidler, Sarah, Ayap, Wilbert, Molina, Marcelino, Waters, Laura, Nur, Fowsiya, Fernandez, Thomas, Nugent, Diarmuid, Pinedo, Javier, Reeves, Iain, Fong, Tracy, Nicholls, Jane, Cunningham, Laura, Pangan, Jaydee, Mackintosh, Claire, Sharp, Louise, Sabin, Caroline A, Van der Valk, Marc, Jarrin, Inma, van Sighem, Ard, Volny Anne, Alain, and Costagliola, Dominique

Published
2024
Full Text
View/download PDF

4. Positive HBs antigen in the absence of hepatitis B virus infection

Author

Cachinho, José Bras, François, Maud, Stefic, Karl, and Marlet, Julien

Subjects
Quantitative Biology - Quantitative Methods
Abstract

French recommendations for the screening of hepatitis B virus (HBV) infection were updated in 2019 with the association of three markers: HBs Ag, anti-HBs Ab and anti-HBc Ab. These three markers allow identification of infected patients, vaccinated patients and patients who have been in contact with HBV. A positive HBs Ag is usually associated with HBV infection but this interpretation must take into account the clinical context. In particular, the absence of anti-HBc Ab, normal ALAT levels and the absence of jaundice can be associated with recent HBV vaccination or false-positive HBs Ag. Recent HBV vaccination can usually be confirmed by patient questioning, while confirmatory tests are useful to detect false positive HBs Ag. If necessary, a second sample can be requested to confirm the interpretation., Comment: in French

Published
2019
Full Text
View/download PDF

6. Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study †.

Author

Zafilaza, Karen, Bellet, Jonathan, Truffot, Aurélie, Foulongne, Vincent, Onambele, Manuela Mireille, Salmona, Maud, Vellas, Camille, Périllaud-Dubois, Claire, Mirand, Audrey, André-Garnier, Elisabeth, Alidjinou, Enagnon Kazali, Brichler, Ségolène, Fenaux, Honorine, Bouvier-Alias, Magali, Hartard, Cédric, Dorival, Céline, Carrat, Fabrice, Marcelin, Anne-Geneviève, Stefic, Karl, and Soulie, Cathia

Abstract

Background: Neutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors. Methods: The COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021). Results: The study included 1004 patients with COVID-19, of whom 691 received Bamlanivimab/Etesevimab and 313 received Casirivimab/Imdevimab. The alpha variant represented 90.1% of those for whom data were available. The risk of hospitalization within 30 days was lower with Bamlanivimab/Etesevimab (12.7%, CI 95% [9.9–16.3%]) compared to Casirivimab/Imdevimab (28.4%, CI 95% [22.7–35.1%) (p < 0.001). The 30-day mortality rates were comparable between both groups (p = 0.982). Analysis of SARS-CoV-2 PCR negativity showed no difference between the two treatment groups (95.2% [93.0–96.9%] and 93.5% [89.1–96.6%] until day 30, p = 0.851 for Bamlanivimab/Etesevimab and Casirivimab/Imdevimab, respectively). Among persistently positive samples with available sequencing results (n = 43), Spike protein changes occurred only in Bamlanivimab/Etesevimab (42.9%) vs. Casirivimab/Imdevimab (0.0%) groups. Q493R (25.0%) and E484K (12.5%) were the most common mutations selected by Bamlanivimab/Etesevimab in follow-up samples. Other factors (immunodepression, comorbidities, and age) did not appear to be associated with the occurrence of Spike protein mutations. Conclusions: A higher rate of hospitalization was seen with Casirivimab/Imdevimab (RONAPREVE®) in comparison with Bamlanivimab/Etesevimab treatment, but with the emergence of Spike mutations only in the Bamlanivimab/Etesevimab group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023.

Author

Chaix, Marie‐Laure, Terracol, Laura, Nere, Marie‐Laure, Stefic, Karl, Lascoux‐Combe, Caroline, Manda, Victoria, Sellier, Pierre, Maylin, Sarah, Molina, Jean‐Michel, Liegeon, Geoffroy, Delaugerre, Constance, and Salmona, Maud

Subjects
NUCLEOSIDE reverse transcriptase inhibitors, REVERSE transcriptase inhibitors, INTEGRASE inhibitors, INFECTION, DRUG resistance
Abstract

Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for maraviroc and broadly neutralizing antibodies (bNAbs) (zinlirvimab and teropavimab). Between 2020 and 2023, 85 people with HIV (PWH) were diagnosed with primary HIV‐1 infection (PHI). Pol and env sequences were analyzed and TDR was characterized according to the French ANRS algorithm. The genotypic‐based prediction of bNAbs sensitivity was based on HIV env amino acid signatures I108, I201, F353 for teropavimab and N325, N332, H330 for zinlirvimab. TDR to NRTIs, NNRTIs, PIs and INIs was evidenced in 8.2%, 12.9%, 4.7%, and 5.9% strains, respectively. Ten viruses were CXCR4/dual mix. All viruses were susceptible to lenacapavir (100%) and 52% harbored resistance to fostemsavir. The genotypic profile was associated with a predictive positive value (PPV) > 83% of susceptibility to both teropavimab and zinlirvimab for 23 viruses (31%), while 22 (29%) had a PPV between 62% and 75%, suggesting reduced susceptibility to both bNAbs as soon as primary infection. The surveillance of TDR evidenced at the time of PHI is important with regard to new strategies for HIV patients with virological failure and global implementation of PrEP using NRTI, INI such as recently approved injectable cabotegravir, and future long‐acting drugs such as lenacapavir and bNAbs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies

Author

Martin de Frémont, Grégoire, primary, Chabrolles, Hélène, additional, Mirand, Audrey, additional, L'Honneur, Anne Sophie, additional, Mélé, Nicolas, additional, Dunogue, Bertrand, additional, Boutboul, David, additional, Farhat, Meryem, additional, Hachulla, Eric, additional, Lazrek, Mouna, additional, Rieu, Virginie, additional, Mathian, Alexis, additional, Chaussade, Helene, additional, Ruet, Aurelie, additional, Burrel, Sonia, additional, Coury-Lucas, Fabienne, additional, Schuffenecker, Isabelle, additional, Lemaignen, Adrien, additional, Stefic, Karl, additional, le Besnerais, Maelle, additional, Carrette, Marion, additional, Mouthon, Luc, additional, Avettand-Fenoel, Veronique, additional, Terrier, Benjamin, additional, and Hadjadj, Jérome, additional

Published
2024
Full Text
View/download PDF

9. Epidemiological and clinical insights into the enterovirus D68 upsurge in Europe 2021/22 and the emergence of novel B3-derived lineages, ENPEN multicentre study

Author

Simoes, Margarida Pires, primary, Hodcroft, Emma B, additional, Simmonds, Peter, additional, Albert, Jan, additional, Alidjinou, Enagon K, additional, Ambert-Balay, Katia, additional, Andrés, Cristina, additional, Antón, Andrés, additional, Auvray, Christelle, additional, Bailly, Jean-Luc, additional, Baldanti, Fausto, additional, Bastings, Capser, additional, Beard, Stuart, additional, Pereira, Carla Berengua, additional, Berginc, Natasa, additional, Bloemen, Mandy, additional, Blomqvist, Soile, additional, Bosma, Froukje, additional, Böttcher, Sindy, additional, Bubba, Laura, additional, Buderus, Stafan, additional, Cabrerizo, Maria, additional, Calvo, Christina, additional, Celma, Christina, additional, Ceriotti, Ferruccio, additional, Clark, Gemma, additional, Costa, Inës, additional, Coste-Burel, Marianne, additional, Couderé, Karen, additional, Cremer, Jeroen, additional, del Cuerpo Casas, Margarita, additional, Daehne, Theo, additional, de Beer, Jessica, additional, de Ceano-Vivas, Maria, additional, De Gascun, Cillian, additional, de Rougemont, Alexis, additional, Dean, Johnathan, additional, Dembinski, Jennifer L, additional, Diedrich, Sabine, additional, Diez-Domingo, Javier, additional, Dillner, Lena, additional, Dorenberg, Dagny H, additional, Ducancelle, Alexandra, additional, Dudman, Susanne, additional, Dyrdak, Robert, additional, Eis-Huebinger, Anna-Maria, additional, Falces-Romero, Iker, additional, Farkas, Agnes, additional, Feeney, Susan, additional, Fernandez-Garcia, Maria D, additional, Flipse, Jacky, additional, Franck, Kristina T, additional, Galli, Cristina, additional, Garrigue, Isabelle, additional, Geeraedts, Felix, additional, Georgieva, Irina, additional, Giardina, Federica, additional, Guiomar, Raquel, additional, Hauzenberger, Elenor, additional, Heikens, Esther, additional, Henquell, Cécille, additional, Hober, Didier, additional, Hönemann, Amrio, additional, Howson-Wells, Hannah, additional, Hruškar, Željka, additional, Ikonen, Niina, additional, Imbert, Berthemarie, additional, Jansz, Arjan R, additional, Jeannoël, Marion, additional, Jiřincová, Helena, additional, Josset, Laurence, additional, Keeren, Kathrin, additional, Kramer-Lindhout, Naomie, additional, Krokstad, Sidsel, additional, Lazrek, Mouna, additional, Le Guillou-Guillemette, Hélène, additional, Lefeuvre, Caroline, additional, Lind, Andreas, additional, Lunar, Maja M, additional, Maier, Melanie, additional, Marque-Juillet, Stéphanie, additional, McClure, C Patrick, additional, McKenna, James, additional, Meijer, Adam, additional, Menasalvas Ruiz, Ana, additional, Mengual-Chuliá, Beatriz, additional, Midgley, Sofie, additional, Mirand, Audrey, additional, Molenkamp, Richard, additional, Montes, Milagrosa, additional, Moreno-Docón, Antonio, additional, Morley, Ursula, additional, Murk, Jean-Luc, additional, Navascués-Ortega, Ana, additional, Nijhuis, Roel, additional, Nikolaeva-Glomb, Lubomira, additional, Nordbø, Svein A, additional, Numanovic, Sanela, additional, Oggioni, Massimo, additional, Oñate Vergara, Eider, additional, Pacaud, Jordi, additional, Pacreau, Marie L, additional, Panning, Marcus, additional, Pariani, Elena, additional, Pekova, Lili, additional, Pellegrinelli, Laura, additional, Petrovec, Miroslav, additional, Pietsch, Corinna, additional, Pilorge, Léa, additional, Piñeiro, Luis, additional, Piralla, Antonio, additional, Poljak, Mario, additional, Prochazka, Birgit, additional, Rabella, Nuria, additional, Rahamat-Langendoen, Janette C, additional, Rainetova, petra, additional, Reynders, Marijke, additional, Riezebos-Brilman, Annelies, additional, Roorda, Lieuwe, additional, Savolainen-Kopra, Carita, additional, Schuffenecker, Isabelle, additional, Smeets, Leo C, additional, Stoyanova, Ayse, additional, Stefic, Karl, additional, Swanink, Caroline, additional, Tabain, Irena, additional, Tjhie, Jeroen, additional, Thouault, Luc, additional, Tumiotto, Camille, additional, Uceda Renteria, Sara, additional, Uršič, Tina, additional, Vallet, Sophie, additional, Van Ranst, Marc, additional, Van Wunnik, Peter, additional, Verweij, Jaco J, additional, Vila, Jorgina, additional, Wintermans, Bas, additional, Wollants, Elke, additional, Wolthers, Katja C, additional, Xavier López-Labrado, F, additional, Fischer, Thea Kolsen, additional, Harvala, Heli, additional, and Benschop, Kimberley S M, additional

Published
2024
Full Text
View/download PDF

10. Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties

Author

Stefic, Karl, Chaillon, Antoine, Bouvin-Pley, Mélanie, Moreau, Alain, Braibant, Martine, Bastides, Frédéric, Gras, Guillaume, Bernard, Louis, and Barin, Francis

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, HIV/AIDS, Neurosciences, Infectious Diseases, Clinical Research, Infection, Good Health and Well Being, Antibodies, Neutralizing, Central Nervous System, HIV Infections, HIV-1, Humans, Longitudinal Studies, Phylogeny, General Science & Technology
Abstract

Compartmentalization of HIV-1 has been observed in the cerebrospinal fluid (CSF) of patients at different clinical stages. Considering the low permeability of the blood-brain barrier, we wondered if a reduced selective pressure by neutralizing antibodies (NAb) in the central nervous system (CNS) could favor the evolution of NAb-sensitive viruses in this compartment. Single genome amplification (SGA) was used to sequence full-length HIV-1 envelope variants (453 sequences) from paired CSF and blood plasma samples in 9 subjects infected by HIV variants of various clades and suffering from diverse neurologic disorders. Dynamics of viral evolution were evaluated with a bayesian coalescent approach for individuals with longitudinal samples. Pseudotyped viruses expressing envelope glycoproteins variants representative of the quasi-species present in each compartment were generated, and their sensitivity to autologous neutralization, broadly neutralizing antibodies (bNAbs) and entry inhibitors was assessed. Significant compartmentalization of HIV populations between blood and CSF were detected in 5 out of 9 subjects. Some of the previously described genetic determinants for compartmentalization in the CNS were observed regardless of the HIV-1 clade. There was no difference of sensitivity to autologous neutralization between blood- and CSF-variants, even for subjects with compartmentalization, suggesting that selective pressure by autologous NAb is not the main driver of HIV evolution in the CNS. However, we observed major differences of sensitivity to sCD4 or to at least one bNAb targeting either the N160-V1V2 site, the N332-V3 site or the CD4bs, between blood- and CSF-variants in all cases. In particular, HIV-1 variants present in the CSF were more resistant to bNAbs than their blood counterpart in some cases. Considering the possible migration from CSF to blood, the CNS could be a reservoir of bNAb resistant viruses, an observation that should be considered for immunotherapeutic approaches.

Published
2017

11. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration

Author

Pantazis, Nikos, Sabin, Caroline A, Grabar, Sophie, Van der Valk, Marc, Jarrin, Inma, van Sighem, Ard, Meyer, Laurence, Carlander, Christina, Gill, John, Volny Anne, Alain, Spire, Bruno, Tariq, Shema, Burns, Fiona, Costagliola, Dominique, Ruiz-Burga, Elisa, Touloumi, Giota, Porter, Kholoud, Moreno, Santiago, Burns, Fiona, Campo, Rafael Eduardo, Garges, Harmony, Mussini, Cristina, Pantazis, Nikos, Kamel, Moustafa, Porter, Kholoud, Sabin, Caroline, Tariq, Shema, Touloumi, Giota, Vannappagari, Vani, Anne, Alain Volny, Young, Lital, Gill, John, Carlander, Christina, Grabar, Sophie, Jarrín, Inma, Meyer, Laurence, van der Valk, Marc, Wittkop, Linda, Aisam, Agnes, Barger, Diana, Davidovich, Udi, Dos Santos, Marie, Eriksson, Lars, Fitzgerald, Eli, Karakosta, Argyro, Krentz, Hartmut, Nicholls, Emily Jay, Policek, Nicoletta, Ruiz-Burga, Elisa, Sandford, Chris, Spire, Bruno, Suárez-García, Inés, Abgrall, Sophie, Andriantsoanirina, Valerie, Avettand-Fenoel, Veronique, Bourgeois, Christine, Chaix, Marie-Laure, Cheret, Antoine, Fischer, Hugues, Goujard, Cecile, Lascoux-Combe, Caroline, Le Palec, Annie, Petrov-Sanchez, Ventzlislava, Saez-Cirion, Asier, Seng, Remonie, Stefic, Karl, Tine, Josephine, Piet, E, Gagneux-Brunon, A, Jacomet, C, Piroth, L, Benezit, F, Goussef, M, Tattevin, P, Bani Sadr, B, Lamaury, I, Bazus, H, Robineau, O, Calin, R, Katlama, J, Denis, B, Ghosn, J, Joly, V, Khuong, M A, Caby, F C, Rouveix Nordon, E, de Truchis, P, Abgrall, S, Chéret, A, Duvivier, C, Becker, A, Miailhes, P, Abel, S, Unal, G, Makinson, A, Martin-Blondel, G, Morisot, A, Bregigeon, S, Enel, P, Allavena, C, Rabier, V, Vallet, L, Marchand, L, Saïdi, T, Costagliola, D, Grabar, S, Piet, E, Andriantsoanirina, V, Rabier, V, Fischer, H, Vallet, L, Marchand T Saïdi, L, Costagliola, D, Grabar, S, Abgrall, Sophie, Tattevin, Pierre, de Truchis, Pierre, Fischer, Hughes, Grabar, Sophie, Moreno, Santiago, Jarrín, Inma, Dalmau, David, Navarro, M Luisa, González, M Isabel, Garcia, Federico, Poveda, Eva, Iribarren, Jose Antonio, Gutiérrez, Félix, Rubio, Rafael, Vidal, Francesc, Berenguer, Juan, Muñoz-Fernández, M Ángeles, Adamis, G, Chini, M, Chrysos, G, Marangos, M, Katsarou, O, Kofteridis, D, Metallidis, S, Panagopoulos, P, Papadopoulos, A, Paparizos, V, Psychogiou, M, Sambatakou, H, Sipsas, N V, Touloumi, G, Fox, Julie, Terry, Louise, Waters, Anele, Uriel, Alison, Ustianowski, Andrew, Hackney, Pamela, Fahd, Niaz, Fidler, Sarah, Ayap, Wilbert, Molina, Marcelino, Waters, Laura, Nur, Fowsiya, Fernandez, Thomas, Nugent, Diarmuid, Pinedo, Javier, Reeves, Iain, Fong, Tracy, Nicholls, Jane, Cunningham, Laura, Pangan, Jaydee, Mackintosh, Claire, and Sharp, Louise

Abstract

Understanding the reasons for and consequences of bodyweight change in people living with HIV initiating antiretroviral therapy (ART) is crucial to optimising long-term health and wellbeing. We aimed to examine bodyweight trends and associated factors among individuals with well estimated dates of HIV-1 seroconversion.

Published
2024
Full Text
View/download PDF

13. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Author

Planas, Delphine, Bruel, Timothée, Grzelak, Ludivine, Guivel-Benhassine, Florence, Staropoli, Isabelle, Porrot, Françoise, Planchais, Cyril, Buchrieser, Julian, Rajah, Maaran Michael, Bishop, Elodie, Albert, Mélanie, Donati, Flora, Prot, Matthieu, Behillil, Sylvie, Enouf, Vincent, Maquart, Marianne, Smati-Lafarge, Mounira, Varon, Emmanuelle, Schortgen, Frédérique, Yahyaoui, Layla, Gonzalez, Maria, De Sèze, Jérôme, Péré, Hélène, Veyer, David, Sève, Aymeric, Simon-Lorière, Etienne, Fafi-Kremer, Samira, Stefic, Karl, Mouquet, Hugo, Hocqueloux, Laurent, van der Werf, Sylvie, Prazuck, Thierry, and Schwartz, Olivier

Published
2021
Full Text
View/download PDF

15. Use of genotypic HIV DNA testing: a DELPHI-type consensus

Author

Andre-Garnier, Elisabeth, primary, Bocket, Laurence, additional, Bourlet, Thomas, additional, Hocqueloux, Laurent, additional, Lepiller, Quentin, additional, Maillard, Anne, additional, Reigadas, Sandrine, additional, Barriere, Guillaume, additional, Durand, François, additional, Montes, Brigitte, additional, Stefic, Karl, additional, and Marcelin, Anne-Geneviève, additional

Published
2024
Full Text
View/download PDF

16. Fatal Measles Inclusion-Body Encephalitis in Adult with Untreated AIDS, France

Author

Rodriguez, Christophe, Gouilh, Meriadeg Ar, Weiss, Nicolas, Stroer, Sebastian, Mokhtari, Karima, Seilhean, Danielle, Mathon, Bertrand, Demontant, Vanessa, N'Debi, Melissa, Gricourt, Guillaume, Woerther, Paul-Louis, Pawlotsky, Jean-Michel, Stefic, Karl, Marlet, Julien, Dequin, Pierre-Francois, Guillon, Antoine, Pourcher, Valerie, Boutolleau, David, Vabret, Astrid, and Burrel, Sonia

Subjects
Measles -- Care and treatment -- Development and progression, Highly active antiretroviral therapy, AIDS (Disease) -- Development and progression -- Care and treatment, Seizures (Medicine) -- Care and treatment -- Development and progression, Encephalitis -- Care and treatment -- Development and progression, Health
Abstract

We report a fatal case of measles inclusion-body encephalitis in a 28-year-old woman from Romania living in France who had untreated AIDS. She was initially admitted to the hospital on [...]

Published
2020
Full Text
View/download PDF

17. Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies.

Author

de Frémont, Grégoire Martin, Chabrolles, Hélène, Mirand, Audrey, L'Honneur, Anne Sophie, Mélé, Nicolas, Dunogue, Bertrand, Boutboul, David, Farhat, Meryem, Hachulla, Eric, Lazrek, Mouna, Rieu, Virginie, Mathian, Alexis, Chaussade, Helene, Ruet, Aurelie, Burrel, Sonia, Coury-Lucas, Fabienne, Schuffenecker, Isabelle, Lemaignen, Adrien, Stefic, Karl, and le Besnerais, Maelle

Published
2024
Full Text
View/download PDF

23. Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe

Author

de Salazar, Adolfo, primary, Viñuela, Laura, additional, Fuentes, Ana, additional, Teyssou, Elisa, additional, Charpentier, Charlotte, additional, Lambert-Niclot, Sidonie, additional, Serrano-Conde, Esther, additional, Pingarilho, Marta, additional, Fabeni, Lavinia, additional, De Monte, Anne, additional, Stefic, Karl, additional, Perno, Carlo Federico, additional, Aguilera, Antonio, additional, Falces, Iker, additional, Delgado, Rafael, additional, Fernandes, Sandra, additional, Diogo, Isabel, additional, Gomes, Perpetua, additional, Paraskevis, Dimitrios, additional, Santoro, Maria-Mercedes, additional, Ceccherini-Silberstein, Francesca, additional, Marcelin, Anne-Geneviève, additional, and Garcia, Federico, additional

Published
2022
Full Text
View/download PDF

24. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection

Author

Planas, Delphine, primary, Staropoli, Isabelle, additional, Porot, Françoise, additional, Guivel-Benhassine, Florence, additional, Handala, Lynda, additional, Prot, Matthieu, additional, Bolland, William-Henry, additional, Puech, Julien, additional, Péré, Hélène, additional, Veyer, David, additional, Sève, Aymeric, additional, Simon-Lorière, Etienne, additional, Bruel, Timothée, additional, Prazuck, Thierry, additional, Stefic, Karl, additional, Hocqueloux, Laurent, additional, and Schwartz, Olivier, additional

Published
2022
Full Text
View/download PDF

25. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies

Author

Bruel, Timothée, Stéfic, Karl, Nguyen, Yann, Toniutti, Donatella, Staropoli, Isabelle, Porrot, Françoise, Guivel-Benhassine, Florence, Bolland, William-Henry, Planas, Delphine, Hadjadj, Jérôme, Handala, Lynda, Planchais, Cyril, Prot, Matthieu, Simon-Lorière, Etienne, André, Emmanuel, Baele, Guy, Cuypers, Lize, Mouthon, Luc, Mouquet, Hugo, Buchrieser, Julian, Sève, Aymeric, Prazuck, Thierry, Maes, Piet, Terrier, Benjamin, Hocqueloux, Laurent, and Schwartz, Olivier

Published
2022
Full Text
View/download PDF

27. Landscape of HIV neutralization susceptibilities across tissue reservoirs.

Author

Wang, Chuangqi, Wang, Chuangqi, Schlub, Timothy E, Yu, Wen-Han, Tan, C Sabrina, Stefic, Karl, Gianella, Sara, Smith, Davey M, Lauffenburger, Douglas A, Chaillon, Antoine, Julg, Boris, Wang, Chuangqi, Wang, Chuangqi, Schlub, Timothy E, Yu, Wen-Han, Tan, C Sabrina, Stefic, Karl, Gianella, Sara, Smith, Davey M, Lauffenburger, Douglas A, Chaillon, Antoine, and Julg, Boris

Abstract

HIV-1 sequence diversity and the presence of archived epitope mutations in antibody binding sites are a major obstacle for the clinical application of broadly neutralizing antibodies (bNAbs) against HIV-1. Specifically, it is unclear to what degree the viral reservoir is compartmentalized and more importantly if virus susceptibility to antibody neutralization differs across tissues. The Last Gift cohort enrolled 7 people with HIV diagnosed with a terminal illness and collected antemortem blood and postmortem tissues across 33 anatomical compartments for near-full-length env HIV-genome sequencing. Using these data, we applied a new Bayesian machine-learning model (MCMC-SVM) that uses HIV-1 envelope sequences and approximated glycan-occupancy information as variables to quantitatively predict the half-maximal-inhibitory concentrations (IC50) of bNAbs. This allowed us to map the landscape of neutralization resistance across each person's tissue reservoirs. Predicted mean susceptibilities across tissues within a participant were relatively homogenous and the susceptibility pattern observed in blood often matched what was predicted for tissues. Selected tissues, like the brain, however, showed in some participants evidence of compartmentalized viral populations with distinct neutralization susceptibilities. Additionally, we found substantial heterogeneity of the range of neutralization susceptibilities across tissues even within an individual, between individuals and also between bNAbs within the same individual (standard deviation of log2(IC50) > 3.4). Blood-based screening methods to determine viral susceptibility to bNAbs might underestimate the presence of resistant viral variants in tissues. To what extent these resistant viruses are clinically relevant, ie. leading to bNAb therapeutic failure, needs to be further explored.

Published
2022

28. Supplementary Information and Source Data for Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells

Author

Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, Bruel, Timothee, Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, and Bruel, Timothee

Published
2022

29. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells

Author

Institut Pasteur, Agence Nationale de la Recherche (France), Ministére de l'Education Nationale de la Recherche et de la Technologie (France), Université de Tours, Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, Bruel, Timothee, Institut Pasteur, Agence Nationale de la Recherche (France), Ministére de l'Education Nationale de la Recherche et de la Technologie (France), Université de Tours, Dufloo, Jeremy, Planchais, Cyril, Frémont, Stéphane, Lorin, Valérie, Guivel-Benhassine, Florence, Stefic, Karl, Casartelli, Nicoletta, Echard, Arnaud, Roingeard, Philippe, Mouquet, Hugo, Schwartz, Olivier, and Bruel, Timothee

Abstract

Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promising molecules for therapeutic or prophylactic interventions. Beyond neutralization, bNAbs exert Fc-dependent functions including antibody-dependent cellular cytotoxicity and activation of the complement. Here, we show that a subset of bNAbs targeting the CD4 binding site and the V1/V2 or V3 loops inhibit viral release from infected cells. We combined immunofluorescence, scanning electron microscopy, transmission electron microscopy and immunogold staining to reveal that some bNAbs form large aggregates of virions at the surface of infected cells. This activity correlates with the capacity of bNAbs to bind to Env at the cell surface and to neutralize cell-free viral particles. We further show that antibody bivalency is required for viral retention, and that aggregated virions are neutralized. We have thus identified an additional antiviral activity of bNAbs, which block HIV-1 release by tethering viral particles at the surface of infected cells.

Published
2022

31. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.

Author

Salazar, Adolfo de, Viñuela, Laura, Fuentes, Ana, Teyssou, Elisa, Charpentier, Charlotte, Lambert-Niclot, Sidonie, Serrano-Conde, Esther, Pingarilho, Marta, Fabeni, Lavinia, Monte, Anne De, Stefic, Karl, Perno, Carlo Federico, Aguilera, Antonio, Falces, Iker, Delgado, Rafael, Fernandes, Sandra, Diogo, Isabel, Gomes, Perpetua, Paraskevis, Dimitrios, and Santoro, Maria-Mercedes

Subjects
HIV infection epidemiology, HIV infection transmission, HIV infections, DRUG efficacy, RALTEGRAVIR, HIV integrase inhibitors, GENETIC mutation, MICROBIAL genetics, TENOFOVIR, ANTIRETROVIRAL agents, LAMIVUDINE, RESEARCH funding, DESCRIPTIVE statistics, INFECTIOUS disease transmission, DRUG resistance in microorganisms, NUCLEOSIDE reverse transcriptase inhibitors, ABACAVIR, EMTRICITABINE, PHARMACODYNAMICS, DISEASE risk factors
Abstract

Background We evaluated the prevalence of transmitted drug resistance (TDR) to integrase strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and of clinically relevant resistance (CRR) in newly diagnosed people with human immunodeficiency virus (HIV; PWH) naive to antiretroviral therapy (ART) in Europe. Methods MeditRes is a consortium that includes ART-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018–2021. Reverse transcriptase and INSTI sequences were provided by participating centers. To evaluate the prevalence of surveillance drug resistance mutations (SDRM), we used the calibrated population resistance tools from the Stanford HIV website. To evaluate CRR, defined as any resistance level ≥3, we used the Stanford HIV Drug Resistance Database v.9.1 algorithm. Results We included 2705 PWH, 72% men, median age of 37 years (interquartile range, 30–48); 43.7% were infected by non-B subtypes. The prevalence of INSTI-SDRMs was 0.30% (T66I, T66A, E92Q, E138T, E138K, Y143R, S147G, R263K; all n=1) and the prevalence of NRTI-SDRMs was 5.77% (M184V: 0.85%; M184I: 0.18%; K65R/N: 0.11%; K70E: 0.07%; L74V/I: 0.18%; any thymidine analog mutations: 4.36%). INSTI-CRR was 2.33% (0.15% dolutegravir/bictegravir, 2.29% raltegravir/elvitegravir) and 1.74% to first-line NRTIs (0.89% tenofovir/tenofovir alafenamide, 1.74% abacavir, 1.07% lamivudine/emtricitabine). Conclusions We present the most recent data on TDR to integrase-based first-line regimens in Europe. Given the low prevalence of CRR to second-generation integrase inhibitors and to first-line NRTIs during 2018–2021, it is unlikely that newly diagnosed PWH in MeditRes countries would present with baseline resistance to a first-line regimen based on second-generation integrase inhibitors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients

Author

Yazdanpanah, Yazdan, DIALLO, Alpha, PAUL, Christelle, MERCIER, Noémie, LE MESTRE, Soizic, PETROV‐SANCHEZ, Ventzislava, ANDREJAK, Claire, CHIROUZE, Catherine, MALVY, Denis, DEPLANQUE, Dominique, DUBOS, François, ROSSIGNOL, Patrick, ETIENNE, Manuel, ROSSIGNOL, Bénédicte, LEVY‐MARCHAL, Claire, GILG, Morgane, GIGANTE, Tristan, Marine, BELUZE, HULOT, Jean‐Sebastien, CHAIR, Anissa, KHALIL, Antoine, VISSEAUX, Benoit, COUFFIGNAL, Camille, ROY, Carine, LAOUÉNAN, Cédric, DA SILVEIRA, Charlene, TARDIVON, Coralie, BACHELET, Delphine, DESCAMPS, Diane, MENTRÉ, France, BOMPART, François, LESCURE, François‐Xavier, PEYTAVIN, Gilles, GORENNE, Isabelle, HOFFMANN, Isabelle, GHOSN, Jade, Christophe LUCET, Jean, TIMSIT, Jean‐François, MULLAERT, Jimmy, BHAVSAR, Krishna, BOUADMA, Lila, TAGHERSET, Lysa, TELLIER, Marie‐Capucine, DEBRAY, Marie‐Pierre, ESPOSITO‐FARESE, Marina, SCHNEIDER, Marion, LE, Minh, ETTALHAOUI, Nadia, SI MOHAMMED, Nassima, GAULT, Nathalie, PEIFFER‐SMADJA, Nathan, KEFIF, Ouifiya, ELOY, Philippine, LE HINGRAT, Quentin, KALI, Sabrina, LARIBI, Samira, TUBIANA, Sarah, TRIOUX, Théo, DUVAL, Xavier, VANEL, Noémie, PICONE, Olivier, BASMACI, Romain, ANGOULVANT, François, KAGUELIDOU, Florentia, PAGES, Justine, VEISLINGER, Aurélie, TUAL, Christelle, PAPADOPOULOS, Aurélie, ESPEROU, Hélène, JAAFOURA, Salma, COUFFIN‐CADIERGUES, Sandrine, COELHO, Alexandra, HOCTIN, Alexandre, DIOUF, Alphonsine, MAMBERT, Marina, GAYMARD, Alexandre, LINA, Bruno, ROSA‐CALATRAVA, Manuel, BOUSCAMBERT, Maude, TERRIER, Olivier, MEZIANE, Amina, DORIVAL, Céline, BENKEROU, Dehbia, TÉOULÉ, François, LINGAS, Guillaume, LE NAGARD, Hervé, GUEDJ, Jérémie, NEANT, Nadège, ABEL, Laurent, KHAN, Coralie, DESVALLÉE, Mathilde, WIEDEMANN, Aurélie, LEVY, Yves, MOUQUET, Hugo, BEHILILL, Sylvie, van der WERF, Sylvie, ENOUF, Vincent, SEMAILLE, Caroline, dORTENZIO, Eric, CERVANTES‐GONZALEZ, Minerva, PUÉCHAL, Oriane, NORET, Marion, RORIZ, Mélanie, RISPAL, Patrick, REDL, Sarah, LEFEBVRE, Laurent, GRANIER, Pascal, MAULIN, Laurence, JOSEPH, Cédric, MOYET, Julien, LION‐DAOLIO, Sylvie, MAHIEU, Rafael, DUCANCELLE, Alexandra, DUBEE, Vincent, SALLABERRY, Stéphane, MANUEL, Aldric, MACHEDA, Gabriel, MAILLET, Mylène, CHANZY, Bruno, GAGNARD, Jean‐Charles, GIORDANO, Guillermo, MOUTON PERROT, Clara, PESTRE, Vincent, FICKO, Cécile, GOMINET, Marie, BOUSQUET, Aurore, VAUCHY, Charline, BOUILLER, Kévin, PAGADOY, Maïder, MARTY‐QUINTERNET, Solène, LEPILLER, Quentin, LE BRIS, Cyril, THILL, Benoit, CASANOVA, Marie‐Laure, LE FALHER, Georges, OZIOL, Eric, CORDEL, Hugues, DOURNON, Nathalie, BOUCHAUD, Olivier, BRICHLER, Ségolène, NGUYEN, Duc, BELLECAVE, Pantxika, CICCONE, Camille, LAFON, Marie‐Edith, GREFFE, Ségolène, BOUISSE, Camille, SEDILLOT, Nicholas, BOUHOUR, Damien, CHASSIN, Camille, LHER, Erwan, ANSART, Séverine, TROMEUR, Cécile, GUELLEC, Dewi, MERCKX, Antoine, DJOSSOU, Felix, PEIGNE, Vincent, PIEROBON, Carola, CARRET, Marie‐Christine, JEGO, Florence, ISNARD, Margaux, AUCHABIE, Johann, COURTOIS, Roxane, LESENS, Olivier, MARTINOT, Martin, LACOSTE, Marie, ELHARRAR, Brigitte, GARRAIT, Valérie, DELACROIX, Isabelle, MAITRE, Thomas, Baptiste ASSIE, Jean, NYAMANKOLLY, Elsa, Xavier CATHERINE, François, BLOT, Mathieu, MAHY, Sophie, BUISSON, Marielle, PIROTH, Lionel, GUILLOTIN, Florence, DE ROUGEMONT, Alexis, CAMPANA, Valentine, PASQUIER, Jérémie, CABIE, André, BESSIS, Simon, EPAULARD, Olivier, TERZI, Nicolas, PAYEN, Jean‐François, BOUILLET, Laurence, HAMIDFAR, Rebecca, Le MARECHAL, Marion, MACHADO, Moïse, BARRELET, Audrey, BEDOSSA, Alexandra, COLIN, Gwenhaël, DECOURS, Romain, GUIMARD, Thomas, GOUJARD, Cécile, JAUREGUIBERRY, Stéphane, CHERET, Antoine, Sophie RESSEGUIER, Anne, POISSY, Julien, MATHIEU, Daniel, NSEIR, Saad, ENGELMANN, Ilka, REMY, Martine, VUOTTO, Fanny, GACHET, Benoit, FAURE, Karine, BOYER‐BESSEYRE, Marielle, Enagnon, Kazali, LAMBERT, Marc, SCHERPEREEL, Arnaud, FRY, Stéphanie, YELNIK, Cécile, BITKER, Laurent, MEZIDI, Mehdi, YONIS, Hodane, BENECH, Nicolas, PERPOINT, Thomas, CONRAD, Anne, ICARD, Vinca, VALETTE, Martine, THIBERVILLE, Simon‐Djamel, REBAUDET, Stanislas, DUSSOL, Bertrand, DIAMANTIS, Sylvain, CHAKVEATZE, Catherine, FLATEAU, Clara, DINOT, Vincent, GACI, Rostane, OUAMARA, Nadia, ILLES, Hajnal‐Gabriela, GERBAUD MORLAES, Louis, DIMET, Jérôme, LE MOING, Vincent, PANSU, Nathalie, LE BIHAN, Clément, MONTES, Brigitte, Sophie BOUREAU, Anne, ALLAVENA, Clotilde, BOUCHEZ, Sabelline, GUERY, Romain, LE TURNIER, Paul, MEAR‐PASSARD, Cécile, FERRE, Virginie, RAPP, Christophe, DEMONCHY, Elisa, MICHELANGELLI, Céline, RISSO, Karine, LOUBET, Paul, LAVIGNE, Jean‐Phillippe, DE MONTMOLLIN, Etienne, PATRIER, Juliette, Henri WICKY, Paul, LE FEVRE, Lucie, JACQUET, Pierre, BORIE, Raphael, DOSSIER, Antoine, LUTON, Dominique, ISERNIA, Valentina, LE GAC, Sylvie, AZOULAY, Cécile, CARLIER, Nicolas, LUONG, Liem, LACHATRE, Marie, LAUNAY, Odile, KERROUMI, Younes, MEYSSONNIER, Vanina, DIEHL, Jean‐Luc, HULOT, Jean‐Sébastien, CHOLLEY, Bernard, ARLET, Jean‐Benoît, SANCHEZ, Olivier, MANDA, Victoria, AZEMAR, Laurène, CASTOR‐ALEXANDRE, Guylaine, LACOMBE, Karine, CHIARABINI, Thibault, LEFEBVRE, Bénédicte, MORAND‐JOUBERT, Laurence, FOFANA, Djeneba, SCHNURIGER, Aurélie, DE CASTRO, Nathalie, DELAUGERRE, Constance, CHAIX, Marie‐Laure, CHAS, Julie, GABORIEAU, Valérie, LE COUSTUMIER, Eve, PICARD, Walter, ZABBE, Jean‐Benoît, PEELMAN, Florent, SOUM, Edouard, AUMAÎTRE, Hugues, CURLIER, Elodie, OUISSA, Rachida, FABRE, Isabelle, RAMMAERT, Blandine, SAIDANI, Nadia, BANI‐SADR, Firouzé, HENTZIEN, Maxime, NGUYEN, Yohan, ROMARU, Juliette, DIDIER, Kévin, ENDERLE, Isabelle, THIBAULT, Vincent, LAINE, Fabrice, LESOUHAITIER, Matthieu, REVEST, Matthieu, TATTEVIN, Pierre, PLANTIER, Jean‐Christophe, LEMEE, Véronique, FERRAND DEVOUGE, Eglantine, ALEXANDRE, Kévin, ARTAUD‐MACCARI, Elise, ALLOU, Nathalie, LAGRANGE, Marie, JABOT, Julien, ROZE, Benoît, BREGEAUD, Delphine, AIT TAMLIHAT, Younes, HACHEMI, Ali, SALVATOR, Hélène, FOURN, Erwan, ZUCMAN, David, DELAVEUVE, Eric, JAUD‐FISCHER, Coline, DUNAND, Paul, BISSUEL, François, DELAVIGNE, Karen, PIEL‐JULIAN, Marie, DELOBEL, Pierre, SARTON, Benjamine, RAFIQ, Marie, MARTIN‐BLONDEL, Guillaume, GUILLEMINAULT, Laurent, MURRIS, Marlène, SOMMET, Agnès, SENNEVILLE, Eric, ROBINEAU, Olivier, MEYBECK, Agnès, GAROT, Denis, PLANTIER, Laurent, GISSOT, Valérie, MARLET, Julien, STEFIC, Karl, GAUDY‐GRAFFIN, Catherine, BARIN, Francis, LEMAIGNEN, Adrien, CORVAISIER, Grégory, LARIVIERE, Delphine, LANGELOT‐RICHARD, Marie, BOTELHO‐NEVERS, Elisabeth, GAGNEUX‐BRUNON, Amandine, TROUILLON, Tiffany, BOURLET, Thomas, PILLET, Sylvie, POZZETTO, Bruno, KIMMOUM, Antoine, LEVY, Bruno, MATTEI, Mathieu, GOEHRINGER, François, RABAUD, Christian, BEVILACQUA, Sibylle, LEFEVRE, Benjamin, GUILLAUMOT, Anne, VENARD, Véronique, JEULIN, Hélène, SCHVOERER, Evelyne, HARTARD, Cédric, CARAUX PAZ, Pauline, RICHIER, Laurent, EL SANHARAWI, Mohamed, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, ANRS France Recherche Nord & sud Sida-hiv hépatites, France REcherche Nord & sud Sida-hiv Hépatites (FRENSH), CHU Amiens-Picardie, Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, French COVID cohort study group, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 (CIC Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), CHU Rouen, Normandie Université (NU), and The Alliance for International Medical Action [Dakar, Sénégal] (ONG ALIMA)

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, Adolescent, prospective cohort, SARS‐CoV‐2, Cohort Studies, Young Adult, coronavirus disease 2019, 03 medical and health sciences, Patient Admission, 0302 clinical medicine, Risk Factors, Virology, Internal medicine, Diabetes mellitus, emerging infection diseases, medicine, Humans, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Research Articles, Aged, Aged, 80 and over, SARS-CoV-2, Proportional hazards model, business.industry, Hazard ratio, Age Factors, COVID-19, Middle Aged, Viral Load, medicine.disease, Obesity, Confidence interval, Hospitalization, Infectious Diseases, Female, 030211 gastroenterology & hepatology, France, business, Viral load, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article
Abstract

Little is known on the association between clinical factors and coronavirus disease 2019 (COVID‐19) more than 15 days after diagnosis. We conducted a multicentric prospective cohort of COVID‐19 hospitalized patients to describe clinical, biological, and virological characteristics at hospital admission and over time, according to mortality up to Day 60 after admission. For the analysis of risk factors of survival, analyses assessing associations between mortality and demographic characteristics or comorbidities were performed using a Cox regression model. Between January 24 and March 15, 2020, 246 patients with reverse‐transcriptase polymerase chain reactions virologically confirmed COVID‐19 were enrolled. In multivariate analysis, mortality at Day 60 (n = 42 patients, 17.1% [95% confidence interval, 12.6–22.4]) was associated with older age (adjusted hazard ratio [aHR] for age ≥ 65 years: 5.22 [2.56–10.63, p, Highlights Older age, male gender, chronic pulmonary disease (not asthma), obesity, and diabetes were associated with mortality in COVID‐19 hospitalized patients. Viral load at admission decreased with the time since symptom onset, with an association with mortality adjusted on clinical risk factors.

Published
2020

36. Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia

Author

Marlet, Julien, primary, Gatault, Philippe, additional, Maakaroun, Zoha, additional, Longuet, Hélène, additional, Stefic, Karl, additional, Handala, Lynda, additional, Eymieux, Sébastien, additional, Gyan, Emmanuel, additional, Dartigeas, Caroline, additional, and Gaudy-Graffin, Catherine, additional

Published
2021
Full Text
View/download PDF

39. Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021

Author

Gaymard, Alexandre, Bosetti, Paolo, Feri, Adeline, Destras, Gregory, Enouf, Vincent, Andronico, Alessio, Burrel, Sonia, Behillil, Sylvie, Sauvage, Claire, Bal, Antonin, Morfin, Florence, Van Der Werf, Sylvie, Josset, Laurence, Blanquart, François, Coignard, Bruno, Cauchemez, Simon, Lina, Bruno, Gault, Elyanne, Moreau, Frédérique, Brichler, Ségolène, Delagrèverie, Héloïse, Descamps, Diane, Charpentier, Charlotte, Rozenberg, Flore, L'Honneur, Anne-Sophie, Veyer, David, Bélec, Laurent, Fourati, Slim, Rodriguez, Christophe, Pawlotsky, Jean-Michel, Fourgeaud, Jacques, Abid, Hanène, Roque-Afonso, Anne-Marie, Fenaux, Honorine, Jary, Aude, Marot, Stéphane, Salmona, Maud, Chaix, Marie-Laure, Morand-Joubert, Laurence, Schnuriger, Aurélie, Juillet, Stéphanie Marque, Bargain, Pauline, Poggi, Cécile, Chollet, Lionel, Guillaume, Clémence, Guinard, Jérôme, Vallet, Sophie, Pilorgé, Léa, Schvoerer, Evelyne, Hartard, Cédric, Castelain, Sandrine, François, Catherine, Ducancelle, Alexandra, Lefeuvre, Caroline, Lepiller, Quentin, Marty-Quinternet, Solène, Bellecave, Pantxika, Tumiotto, Camille, Dina, Julia, Le Gouil, Meriadeg, Henquell, Cécile, Mirand, Audrey, Césaire, Raymond, de Rougemont, Alexis, Auvray, Christelle, Larrat, Sylvie, Némoz, Benjamin, Tinez, Claire, Guigon, Aurélie, Hantz, Sébastien, Rogez, Sylvie, Dos Santos, Georges, Perez, Pascale, Jost, Christelle, Montes, Brigitte, Foulongne, Vincent, Imbert, Berthe-Marie, Bressollette, Céline, Giordanengo, Valérie, Gonfrier, Géraldine, Garcia, Magali, Lévêque, Nicolas, Brodard, Véronique, Moret, Hélène, Thibault, Vincent, Maillard, Anne, Jaffar-Bandjee, Marie-Christine, Gueudin, Marie, Plantier, Jean-Christophe, Pozzetto, Bruno, Pillet, Sylvie, Fafi-Kremer, Samira, Solis, Morgane, Izopet, Jacques, Trémeaux, Pauline, Stefic, Karl, Handala, Lynda, Billaud, Geneviève, Frobert, Emilie, Mérens, Audrey, Bigaillon, Christine, Desroches, Marine, Thepenier, Cédric, Janvier, Frédéric, Otto, Marie-Pierre, Roquebert, Bénédicte, Haïm-Boukobza, Stéphanie, Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL), Virpath-Grippe, de l'émergence au contrôle -- Virpath-Influenza, from emergence to control (Virpath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Modélisation mathématique des maladies infectieuses - Mathematical modelling of Infectious Diseases, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Direction des maladies infectieuses - Infectious Diseases Division [Saint-Maurice], Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Laboratoire de Virologie [CHU Amiens], CHU Amiens-Picardie, ANRS - Maladies infectieuses émergentes (ANRS - MIE), Institut National de la Santé et de la Recherche Médicale (INSERM), We acknowledge financial support from Santé publique France (the French national public health agency), the French Ministry of health (Grant COVIDseq), the Consortium for the surveillance and research on emerging pathogens via microbial genomics (EMERGEN) coordinated by Santé publique France and ANRS Maladies Infectieuses Emergentes, the Investissement d’Avenir programme, the Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases programme (grant ANR-10-LABX-62-IBEID), the European Union’s Horizon 2020 research and in-novation programme under grants 101003589 (RECOVER). This work has been supported by the laboratories belonging to the ColVHB network*., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 101003589, H2020-SC1-PHE-CORONAVIRUS-2020,RECOVER(2020), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR), Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Gestionnaire, Hal Sorbonne Université, Integrative Biology of Emerging Infectious Diseases - - IBEID2010 - ANR-10-LABX-0062 - LABX - VALID, Rapid European COVID-19 Emergency Response research - RECOVER - - H2020-SC1-PHE-CORONAVIRUS-20202020-02-14 - 2022-02-13 - 101003589 - VALID, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris)

Subjects
Author's Correction, Paris, medicine.medical_specialty, 2019-20 coronavirus outbreak, Lineage (genetic), Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viral infections, [SDV]Life Sciences [q-bio], Context (language use), Biology, 03 medical and health sciences, 0302 clinical medicine, Virology, medicine, Humans, MESH: COVID-19, MESH: SARS-CoV-2, 030212 general & internal medicine, 030304 developmental biology, COVID, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, 0303 health sciences, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, MESH: Humans, SARS-CoV-2, MESH: Paris, Public Health, Environmental and Occupational Health, COVID-19, [SDV] Life Sciences [q-bio], MESH: France, 20I/501Y.V1, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, surveillance, France, mutation, Rapid Communication, Demography
Abstract

International audience; The emergence of SARS-CoV-2 variant 20I/501Y.V1 (VOC-202012/1 or GR/501Y.V1) is concerning given its increased transmissibility. We reanalysed 11,916 PCR-positive tests (41% of all positive tests) performed on 7-8 January 2021 in France. The prevalence of 20I/501Y.V1 was 3.3% among positive tests nationwide and 6.9% in the Paris region. Analysing the recent rise in the prevalence of 20I/501Y.V1, we estimate that, in the French context, 20I/501Y.V1 is 52-69% more transmissible than the previously circulating lineages, depending on modelling assumptions.

Published
2021

40. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France

Author

Woudenberg, Tom, primary, Pelleau, Stéphane, additional, Anna, François, additional, Attia, Mikael, additional, Donnadieu, Françoise, additional, Gravet, Alain, additional, Lohmann, Caroline, additional, Seraphin, Hélène, additional, Guiheneuf, Raphaël, additional, Delamare, Catherine, additional, Stefic, Karl, additional, Marlet, Julien, additional, Brochot, Etienne, additional, Castelain, Sandrine, additional, Augereau, Olivier, additional, Sibilia, Jean, additional, Dubos, François, additional, Meddour, Damia, additional, Guen, Christèle Gras-Le, additional, Coste-Burel, Marianne, additional, Imbert-Marcille, Berthe-Marie, additional, Chauvire-Drouard, Anne, additional, Schweitzer, Cyril, additional, Gatin, Amélie, additional, Lomazzi, Sandra, additional, Joulié, Aline, additional, HAAS, Hervé, additional, Cantais, Aymeric, additional, Bertholon, Frederique, additional, Chinazzo-Vigouroux, Marie-France, additional, Abdallah, Mohamed SI, additional, Arowas, Laurence, additional, Charneau, Pierre, additional, Hoen, Bruno, additional, Demeret, Caroline, additional, Werf, Sylvie Van Der, additional, Fontanet, Arnaud, additional, and White, Michael, additional

Published
2021
Full Text
View/download PDF

42. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to December 2020

Author

Bal, Antonin, Destras, Gregory, Gaymard, Alexandre, Stefic, Karl, Marlet, Julien, Eymieux, Sébastien, Regue, Hadrien, Semanas, Quentin, d’Aubarede, Constance, Billaud, Geneviève, Laurent, Frédéric, Gonzalez, Claudia, Mekki, Yahia, Valette, Martine, Bouscambert, Maude, Gaudy-Graffin, Catherine, Lina, Bruno, Morfin, Florence, Josset, Laurence, Casalegno, Jean-Sébastien, Frobert, Emilie, Escuret, Vanessa, Icard, Vinca, Jeannoel, Marion, Milon, Marie-Paule, Ramière, Christophe, Scholtès, Caroline, Tardy, Jean-Claude, Trabaud, Mary-Anne, Schuffenecker, Isabelle, Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), The members of the COVID-Diagnosis HCL Study Group : Jean-Sébastien Casalegno, Emilie Frobert, Vanessa Escuret, Vinca Icard, Marion Jeannoel, Marie-Paule Milon, Christophe Ramière, Caroline Scholtès, Jean-Claude Tardy, Mary-Anne Trabaud, Isabelle Schuffenecker, Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Marlet, Julien, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours, and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)

Subjects
0301 basic medicine, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 030106 microbiology, Two step, spike protein, variants, deletion, Genome, Viral, Biology, spike protein, Genome, 03 medical and health sciences, COVID-19, whole genome sequencing, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Virology, Humans, Spike (database), Base sequence, Sequence Deletion, whole genome sequencing, variants, Base Sequence, deletion, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, 030104 developmental biology, Spike Glycoprotein, Coronavirus, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Identification (biology), France, Rapid Communication
Abstract

International audience; We report the strategy leading to the first detection of variant of concern 202012/01 (VOC) in France (21 December 2020). First, the spike (S) deletion H69-V70 (ΔH69/ΔV70), identified in certain SARS-CoV-2 variants including VOC, is screened for. This deletion is associated with a S-gene target failure (SGTF) in the three-target RT-PCR assay (TaqPath kit). Subsequently, SGTF samples are whole genome sequenced. This approach revealed mutations co-occurring with ΔH69/ΔV70 including S:N501Y in the VOC.

Published
2021

44. Low-level HIV viremia is associated with low antiretroviral prescription refill rates and social deprivation

Author

Grammatico-Guillon, Leslie, Goupil de Bouillé, Jeanne, Collignon, Marion, Capsec, Jean, Guillon, Leslie, Le Moal, Gwenael, Barin, Francis, Roncato, Mariam, Hocqueloux, Laurent, Stefic, Karl, Bernard, Louis, Gras, Guillaume, and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
Adult, medicine.medical_specialty, Health (social science), Social Psychology, Anti-HIV Agents, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), Viremia, HIV Infections, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Low level viremia, medicine, Humans, 030212 general & internal medicine, Medical prescription, Pharmacy refill, ComputingMilieux_MISCELLANEOUS, 030505 public health, business.industry, Public Health, Environmental and Occupational Health, Middle Aged, Viral Load, medicine.disease, Optimal management, 3. Good health, Social deprivation, Prescriptions, 0305 other medical science, business
Abstract

Optimal management of patients experiencing persistent low-level viremia (LLV) remains challenging and poorly understood. This study aimed to assess the association between poor antiretroviral treatment (ARV) adherence and persistent LLV. ADHELOW is a sub-study of the ECHEC cohort comprising HIV-infected adults with virological failure (viral load50 copies/mL). Patients were recruited in 2013-2015 from 4 French university hospitals. Those with LLV (i.e., ≥2 viral load measurements between 50 and 500 copies/mL) were selected and matched on age and sex to 3 controls with virological suppression. The adherence rate was estimated using pharmacy-delivered prescription refills over one year. Overall, 60 patients were included (15 LLV and 45 controls). Mean age was 50.20 years, M/F sex ratio was 14 and mean EPICES (social deprivation) score was 42.90. In univariable analyses, LLV patients had significantly lower adherence (80%: 53.30% vs. 6.67%

Published
2020

45. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Author

Planas, Delphine, primary, Bruel, Timothée, additional, Grzelak, Ludivine, additional, Guivel-Benhassine, Florence, additional, Staropoli, Isabelle, additional, Porrot, Françoise, additional, Planchais, Cyril, additional, Buchrieser, Julian, additional, Rajah, Maaran Michael, additional, Bishop, Elodie, additional, Albert, Mélanie, additional, Donati, Flora, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, Maquart, Marianne, additional, Gonzalez, Maria, additional, De Sèze, Jérôme, additional, Péré, Hélène, additional, Veyer, David, additional, Sève, Aymeric, additional, Simon-Lorière, Etienne, additional, Fafi-Kremer, Samira, additional, Stefic, Karl, additional, Mouquet, Hugo, additional, Hocqueloux, Laurent, additional, van der Werf, Sylvie, additional, Prazuck, Thierry, additional, and Schwartz, Olivier, additional

Published
2021
Full Text
View/download PDF

48. Screening for Human Immunodeficiency Virus Infection by Use of a Fourth-Generation Antigen/Antibody Assay and Dried Blood Spots: In-Depth Analysis of Sensitivity and Performance Assessment in a Cross-Sectional Study

Author

Stefic, Karl, primary, Guinard, Jerome, additional, Peytavin, Gilles, additional, Saboni, Leïla, additional, Sommen, Cécile, additional, Sauvage, Claire, additional, Lot, Florence, additional, Laperche, Syria, additional, Velter, Annie, additional, and Barin, Francis, additional

Published
2019
Full Text
View/download PDF

50. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

Author

Visseaux, Benoit, Assoumou, Lambert, Grude, Maxime, Carles, Marie-Josée, Meyer, Laurence, Roussel, Catherine, Le Guillou-Guillemette, H., Ducancelle, A., Courdavault, L, Alloui, C, Honore, P, Lepiller, Q., Bettinger, D., Bellecave, P., Pinson-Recordon, P, Tumiotto, Camille, Vallet, Sophie, Payan, C., Duthe, J, Leroux, M., Dina, Julia, Vabret, A., Mirand, A., Henquell, C., Bouvier-Alias, Magali, Simohamed, A, dos Santos, G, yerly, S, Gaille, C, Caveng, W, Chapalay, S, Calmy, A., Signori-Schmuck, Anne, Morand, Patrice, Pallier, Coralie, Raho-Moussa, M, Mole, M, Dulucq, M-J, Bocket, Laurence, Alidjinou, K, Ranger-Rogez, S, Trabaud, Mary-Anne, Icard, V, Tardy, J., Tamalet, C., Delamare, C, Montes, Brigitte, Schvoerer, E., Fenaux, H., Rodallec, A., André-Garnier, E., Ferre, Virginie, de Monte, Anne, Guigon, A., Guinard, J., Descamps, Diane, Charpentier, C., Peytavin, G., Tremaux, P, Avettand-Fenoel, V., Soulie, C., Malet, I., Wirden, Marc, Marcelin, A, Calvez, V., Flandre, P., Costagliola, D, Morand-Joubert, Laurence, Lambert-Niclot, S., Fofana, D, Boukli, N., Delaugerre, C., Chaix, Marie-Laure, Mahjoub, Nadia, Amiel, Corinne, Giraudeau, G, Beby-Defaux, A., Plainchamp, D, Maillard, Anne, Alessandri-Gradt, E, Leoz, M, Plantier, Jean-Christophe, Gantner, P, Delagreverie, H, Fafi-Kremer, Samira, Fischer, P, Raymond, Stéphanie, Izopet, Jacques, Chiabrando, J, Stefic, Karl, Barin, F., Fajole, G, Burgault, O, Marque-Juillet, S, Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), virology, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de recherche sur l'hétéroepitaxie et ses applications (CRHEA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Clermont-Ferrand, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Geneva University Hospital (HUG), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôtel-Dieu de Nantes, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Pharmacie de l'Hôpital Bichat, Centre de Recherches Pétrographiques et Géochimiques (CRPG), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Virologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Unité de Rétrovirologie, Hôpital Pontchaillou, Normandie Université (NU), Laboratoire de Virologie, CHU Strasbourg, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Service de bactériologie-virologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre national de référence du VIH INSERM U966, Université de Tours (UT), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Besançon, Université de Franche-Comté (UFC), Université Grenoble Alpes (UGA), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] (PEGASE), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Male, Etravirine, HIV Infections, Men who have sex with men, Sexual and Gender Minorities, chemistry.chemical_compound, Pre-exposure prophylaxis, 0302 clinical medicine, Pharmacology (medical), 030212 general & internal medicine, Phylogeny, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, education.field_of_study, Virulence, biology, [SDE.IE]Environmental Sciences/Environmental Engineering, Middle Aged, Viral Load, 3. Good health, Integrase, Infectious Diseases, Rilpivirine, Epidemiological Monitoring, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Female, France, Viral load, medicine.drug, Adult, Microbiology (medical), Genotype, Anti-HIV Agents, [SDE.MCG]Environmental Sciences/Global Changes, Population, Evolution, Molecular, 03 medical and health sciences, Drug Resistance, Viral, medicine, Humans, education, Pharmacology, 030306 microbiology, Genetic Variation, Sequence Analysis, DNA, [SDE.ES]Environmental Sciences/Environmental and Society, Virology, chemistry, Mutation, HIV-1, biology.protein, [SDE.BE]Environmental Sciences/Biodiversity and Ecology
Abstract

ObjectivesPatients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.MethodsA total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.ResultsPatients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P = 0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.ConclusionsSince 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results